Abstract
States (1). The median survival of all PDAC cases is less than 6 months, and only 6% 4 of patients survive 5 years after diagnosis. The dismal prognosis in pancreatic cancer is 5 due to late diagnosis and the lack of effective treatment. A better understanding of the 6 molecular mechanism of this disease and discovery of novel therapeutic targets are 7 desperately needed to improve outcomes in patients with PDAC.
8
FOXL1 proteins belong to the forkhead box (Fox) family of transcription factors.
9
Fox family shares a highly conserved 100-aa DNA binding domain (the forkhead box) 10 and comprises more than 100 members in humans, classified as FOXA to FOXR on the 
Materials and Methods

19
Tissue Collection and RNA Isolation clinical staging, resection margin status, and survival times from diagnosis (Table S1 ).
5
Tumor histopathology was classified according to the World Health Organization System, Carpinter, CA). Immunostaining was evaluated blindly by two Board-certified 6 pathologist assigning the intensity and prevalence score as described elsewhere (14).
7
Briefly, the intensity was assigned a score of 0-3, representing negative, weak, 8 moderate or strong expression, whereas, prevalence was assigned a score of 0-4 9 representing <10%, 10-30%, 30-50%, 50-80% and >80% cells showing FOXL1 10 expression. The overall quantitation of IHC score was then achieved by multiplying the 11 intensity and prevalence score as described elsewhere (15). IHC images were 12 photographed under an Olympus BX40 microscope. Cells were seeded in 96-well plates (3,000 cells/well) and incubated for 2-10 5 days. Then, the MTT solution was added and incubated for 4 hours. After the MTT 6 solution was aspirated, 100ul dimethylsulfoxide (DMSO) was added to each well. The 7 absorbance was measured at 570nm and 650 nm. 
Results
15
Higher FOXL1 is associated with better clinical outcome in pancreatic cancer. 16 We performed qRT-PCR for FOXL1 in 45 tumor samples of PDAC and analyzed 17 its association with disease outcome. We dichotomized high and low expression of Meier log-rank test, Figure 1A ). Figure 1D ). These data indicated that FOXL1 may be involved in Figure 3D ). These findings indicate that FOXL1 induces the 16 expression and promoter activity of TRAIL.
17
We further defined the role of TRAIL in FOXL1-induced apoptosis using an 
these results indicate that FOXL1 promotes apoptosis in pancreatic cancer, at least 1 partly, through the induction of TRAIL expression. Figure 5C ). The strongest association was detected around region-4 within the ZEB1 17 promoter (P<0.01). We next tested whether this interaction affects ZEB1 transcription.
18
The promoter region of ZEB1 harboring region-4 was inserted into the pGL4 basic 19 reporter vector (pGL4-ZEB1). Luciferase activity was determined following co-20 transfection of pGL4-ZEB1 with pCMV-FOXL1 or pCMV control vector. As shown in 21 Figure 5D , the luciferase activities of pGL4-ZEB1 were significantly decreased when it 22 was co-transfected with pCMV-FOXL1 compared to pCMV-CTRL (P<0.01, Figure 5D ). These findings showed that FOXL1 bound to the promoter region of ZEB1 and 1 suppressed transcription and promoter activity of ZEB1. found that FOXL1 expression is consistently decreased in multiple myeloma as 7 compared to normal tissues, with a cut-off P value<0.05 in microarray studies (19-21).
8
One myeloma dataset also showed that FOXL1 is significantly higher in long survival 9 (alive over a year) as compared with short survival group (dead within a year) (20). Furthermore, we identified ZEB1 as a novel transcriptional target of FOXL1. In addition to the death receptor ligands, FOXO proteins have been shown to be Further studies are warranted to determine the molecular mechanism driving the loss of 8 FOXL1 during pancreatic cancer progression and how the restoration of FOXL1 can be 9 harnessed for therapeutic benefit. 
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